Stock listing
Frankfurt:2QB0 Ocumetics Technology Corp Aktie
German listing (Frankfurt) of Ocumetics Technology Corp · home listing TSXV:OTC
Follow Ocumetics Technology Corp into a list and get an email when it puts out news.
Share price · FWB:2QB0
€0.19 EUR 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- €0.19 – €0.19 EURNov 20, 2026
- Market cap
- €24.71M EURAt the close on Nov 20, 2026 · price × 130.0M shares outstanding
- 52-week range
- €0.19 – €0.524 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €16 EURMedian day 0 shares · 56 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:OTC · Home | $0.38 CAD | +0.01 (+2.7%) | 29,809 | $0.375 | $0.38 | $0.37 | $0.37 | Close on Nov 20, 2026 |
| OTC:OTCFF | $0.27 USD | +0.01 (+4.0%) | 9,000 | $0.267 | $0.27 | $0.267 | $0.26 | Close on Nov 19, 2026 |
| Frankfurt:2QB0 | €0.19 EUR | 0.00 (0.0%) | — | €0.19 | €0.19 | €0.19 | €0.19 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:2QB0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.20 | -0.006 | -2.9% | €0.20 | €0.20 | €0.20 | 0 | |
| €0.206 | +0.006 | +3.0% | €0.206 | €0.206 | €0.206 | 0 | |
| €0.20 | +0.001 | +0.5% | €0.20 | €0.20 | €0.20 | 0 | |
| €0.199 | -0.001 | -0.5% | €0.199 | €0.199 | €0.199 | 0 | |
| €0.20 | -0.003 | -1.5% | €0.20 | €0.20 | €0.20 | 0 | |
| €0.203 | -0.002 | -1.0% | €0.203 | €0.203 | €0.203 | 0 | |
| €0.205 | -0.003 | -1.4% | €0.205 | €0.205 | €0.205 | 0 | |
| €0.208 | +0.002 | +1.0% | €0.208 | €0.208 | €0.208 | 0 | |
| €0.206 | -0.002 | -1.0% | €0.206 | €0.206 | €0.206 | 0 | |
| €0.208 | +0.002 | +1.0% | €0.208 | €0.208 | €0.208 | 0 | |
| €0.206 | +0.003 | +1.5% | €0.206 | €0.206 | €0.206 | 0 | |
| €0.203 | 0.00 | 0.0% | €0.203 | €0.203 | €0.203 | 0 | |
| €0.203 | -0.015 | -6.9% | €0.203 | €0.203 | €0.203 | 0 | |
| €0.218 | +0.015 | +7.4% | €0.218 | €0.218 | €0.218 | 0 | |
| €0.203 | +0.008 | +4.1% | €0.203 | €0.203 | €0.203 | 0 | |
| €0.195 | -0.006 | -3.0% | €0.195 | €0.195 | €0.195 | 0 | |
| €0.201 | -0.006 | -2.9% | €0.201 | €0.201 | €0.201 | 0 | |
| €0.207 | -0.002 | -1.0% | €0.207 | €0.207 | €0.207 | 0 | |
| €0.209 | 0.00 | 0.0% | €0.209 | €0.209 | €0.209 | 0 | |
| €0.209 | -0.005 | -2.3% | €0.209 | €0.209 | €0.209 | 0 | |
| €0.214 | 0.00 | 0.0% | €0.214 | €0.214 | €0.214 | 0 | |
| €0.214 | 0.00 | 0.0% | €0.214 | €0.214 | €0.214 | 0 | |
| €0.214 | +0.008 | +3.9% | €0.214 | €0.214 | €0.214 | 0 | |
| €0.206 | -0.001 | -0.5% | €0.206 | €0.206 | €0.206 | 0 | |
| €0.207 | -0.005 | -2.4% | €0.207 | €0.207 | €0.207 | 0 | |
| €0.212 | -0.004 | -1.9% | €0.212 | €0.212 | €0.212 | 0 | |
| €0.216 | -0.016 | -6.9% | €0.216 | €0.216 | €0.216 | 0 | |
| €0.232 | +0.003 | +1.3% | €0.232 | €0.232 | €0.232 | 0 | |
| €0.229 | -0.002 | -0.9% | €0.229 | €0.229 | €0.229 | 0 | |
| €0.231 | +0.002 | +0.9% | €0.231 | €0.231 | €0.231 | 0 | |
| €0.229 | -0.002 | -0.9% | €0.229 | €0.229 | €0.229 | 0 | |
| €0.231 | +0.002 | +0.9% | €0.231 | €0.231 | €0.231 | 0 | |
| €0.229 | -0.009 | -3.8% | €0.229 | €0.229 | €0.229 | 0 | |
| €0.238 | +0.003 | +1.3% | €0.238 | €0.238 | €0.238 | 0 | |
| €0.235 | -0.008 | -3.3% | €0.235 | €0.235 | €0.235 | 0 | |
| €0.243 | +0.015 | +6.6% | €0.243 | €0.243 | €0.243 | 0 | |
| €0.228 | -0.001 | -0.4% | €0.228 | €0.228 | €0.228 | 0 | |
| €0.229 | +0.001 | +0.4% | €0.229 | €0.229 | €0.229 | 0 | |
| €0.228 | +0.004 | +1.8% | €0.228 | €0.228 | €0.228 | 0 | |
| €0.224 | -0.012 | -5.1% | €0.224 | €0.224 | €0.224 | 0 | |
| €0.236 | -0.005 | -2.1% | €0.236 | €0.236 | €0.236 | 0 | |
| €0.241 | -0.014 | -5.5% | €0.241 | €0.241 | €0.241 | 0 | |
| €0.255 | +0.004 | +1.6% | €0.255 | €0.255 | €0.255 | 0 | |
| €0.251 | +0.001 | +0.4% | €0.251 | €0.251 | €0.251 | 0 | |
| €0.25 | +0.01 | +4.2% | €0.25 | €0.25 | €0.25 | 0 | |
| €0.24 | -0.066 | -21.6% | €0.24 | €0.24 | €0.24 | 0 | |
| €0.306 | +0.083 | +37.2% | €0.232 | €0.307 | €0.231 | 3,000 | |
| €0.223 | -0.001 | -0.4% | €0.223 | €0.223 | €0.223 | 0 | |
| €0.224 | +0.001 | +0.4% | €0.224 | €0.224 | €0.224 | 0 | |
| €0.223 | -0.002 | -0.9% | €0.223 | €0.223 | €0.223 | 0 | |
| €0.225 | +0.01 | +4.7% | €0.225 | €0.225 | €0.225 | 0 | |
| €0.215 | -0.002 | -0.9% | €0.215 | €0.215 | €0.215 | 0 | |
| €0.217 | +0.007 | +3.3% | €0.217 | €0.217 | €0.217 | 0 | |
| €0.21 | +0.008 | +4.0% | €0.21 | €0.21 | €0.21 | 0 | |
| €0.202 | -0.002 | -1.0% | €0.202 | €0.202 | €0.202 | 0 | |
| €0.204 | -0.008 | -3.8% | €0.204 | €0.204 | €0.204 | 0 | |
| €0.212 | 0.00 | 0.0% | €0.212 | €0.212 | €0.212 | 0 |
- Ticker
- Frankfurt:2QB0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Ocumetics Poised for Value-Defining Group Two First-in-Human Lens Implantations
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 37 slides
Latest news
Ocumetics Announces Changes to Board of Directors; Appoints Sandi Gilbert as Director and Dean Burns as Chairman
Oct 29, 2026
Closed €0.205 (-1.4%) on Oct 29, 2026
Ocumetics Provides Summary of Group One Patient Clinical Progress
Sep 17, 2026
Closed €0.228 (-0.4%) on Sep 17, 2026
Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries
Sep 8, 2026
Closed €0.255 (+1.6%) on Sep 9, 2026
Ocumetics Completes Manufacturing of Next Generation Solid State Accommodating Intraocular Lenses for Upcoming Group Two First in Human Clinical Surgeries
Aug 31, 2026
Closed €0.223 (-0.9%) on Aug 31, 2026
Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement
Aug 24, 2026
Closed €0.202 (-1.0%) on Aug 24, 2026
Ocumetics Announces Completion of Second Tranche of Unit Private Placement
Jul 31, 2026
Closed €0.229 (+2.7%) on Aug 3, 2026
Ocumetics Announces Upsizing of Unit Private Placement
Jul 30, 2026
Closed €0.223 (-5.1%) on Jul 31, 2026
Ocumetics Announces Corporate and Operational Update as Positive Six-Month Clinical Results Advance Next Phase of First-in-Human Study
Jul 9, 2026
Closed €0.196 (-12.9%) on Jul 9, 2026
Ocumetics Announces Significant Debt Conversion Strengthening Balance Sheet Ahead of Patient Study Milestones
Jun 2, 2026
Closed €0.285 (-0.3%) on Jun 2, 2026
Ocumetics Technology Corp on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 26 in the last 12 months · 92 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 9 decks · latest November 2026
Where Ocumetics Technology Corp is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:OTC · Home listing | TSXV | Canada | CAD |
| OTC:OTCFF | OTC | United States | USD |
| Cboe Canada:OTC | Cboe Canada | Canada | CAD |
| Frankfurt:2QB0 · This page | Frankfurt | Germany | EUR |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $53.93M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.14
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ocumetics Technology Corp · TSXV:OTC | US$37.38M | US$37.60M | n/a | n/a | n/a | n/a | n/a | n/a | 0.14 |
| electroCore, Inc. · NASDAQ:ECOR | US$40.78M | US$41.51M | n/a | 1.1× | n/a | n/a | −33.5% | n/a | 1.91 |
| Elutia, Inc. · NASDAQ:ELUT | US$39.86M | US$18.87M | 0.7× | 1.5× | n/a | 2.6× | 441.2% | 0.5× | -0.06 |
| DRGEM Corp. · KRX:263690 | US$38.81M | US$32.33M | 4.3× | 0.4× | 3.2× | 0.5× | 11.2% | 0.1× | n/a |
| Cryofocus Medtech (Shanghai) Co. Ltd. Class H · HKEX:6922 | US$37.93M | US$29.03M | n/a | 2.0× | n/a | 3.8× | −40.1% | 0.0× | n/a |
| Optomed Oyj Class A · OMXHEX:OPTOMED | US$37.24M | US$32.48M | n/a | 1.8× | n/a | 1.6× | −33.9% | 0.1× | n/a |
| Sensus Healthcare, Inc. · NASDAQ:SRTS | US$37.20M | US$24.56M | n/a | 1.5× | n/a | 1.1× | −96.5% | 0.0× | 1.08 |
| Epiminder Ltd. · ASX:EPI | US$36.57M | −US$13.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | n/a |
| Avita Corporation · TPEX:4735 | US$35.63M | US$14.80M | 5.1× | 0.5× | 4.4× | 1.0× | 23.8% | 0.0× | n/a |
| SELVAS Healthcare, Inc. · KRX:208370 | US$35.56M | US$15.07M | 5.5× | 0.6× | 8.0× | 0.6× | 27.5% | 0.0× | n/a |
| Taiwan Biomaterial Co., Ltd. · TPEX:6649 | US$35.55M | US$28.06M | 35.3× | 5.1× | 26.5× | 1.8× | 18.2% | 0.0× | n/a |
| Median of the others | US$37.22M | US$26.31M | 5.1× | 1.5× | 6.2× | 1.1× | 11.2% | 0.0× | 1.08 |
Team and board
Officers
| Officer | Role |
|---|---|
| Dean E. Burns | PRESIDENT / CEO / DIRECTOR |
| Roger Jewett | CFO / DIRECTOR |
| David Burwell | Director, Investor Relations |
| Doyle Stulting | Chief Medical Officer |
| GARTH WEBB | FOUNDER / CSO / DIRECTOR |
Board
| Director | Role |
|---|---|
| Dean E. Burns | PRESIDENT / CEO / DIRECTOR |
| GARTH WEBB | FOUNDER / CSO / DIRECTOR |
| James Barton McRoberts | DIRECTOR |
| Michael Edwards | DIRECTOR |
| Raymond Marks | DIRECTOR |
| Robert Quinn | DIRECTOR |
| Roger Jewett | CFO / DIRECTOR |
| Sandi Gilbert | Director |
Events
- Next results
- Nov 24, 2026 (expected)
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 37 slides | November 2026 |
| Investor Presentation (March 2026) | Investor deck | 37 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 22 slides | March 2026 |
| Investor Presentation (November 2025) | Investor deck | 36 slides | November 2025 |
| Investor Presentation (November 2025) | Investor deck | 19 slides | November 2025 |
| Investor Presentation (June 2025) | Investor deck | 36 slides | June 2025 |
| Investor Presentation (March 2025) | Investor deck | 36 slides | March 2025 |
| Investor Presentation (July 2024) | Investor deck | 36 slides | July 2024 |
| Investor Presentation (September 2023) | Investor deck | 36 slides | September 2023 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Closed: C$3.11M raised · C$0.4 a unit · 1 warrant at C$0.5 for 36 months · Ventum Financial Corp. +1 Dealers: Ventum Financial Corp. (finder), Canaccord Genuity Corp. (finder) Use of proceeds: First-in-human clinical trials, ongoing research and development and general working capital | Aug 24, 2026 | |
| Not stated Update: raise Use of proceeds: Fund completion of the first-in-human clinical study and support manufacturing, regulatory and commercialization activities | Jul 9, 2026 | |
| Private placement of units Announced: up to C$1.54M · C$0.55 a unit · 1 warrant at C$0.75 for 36 months Use of proceeds: First in-human clinical trials, ongoing research and development, and general working capital | Apr 29, 2026 | US$1.13M |
| Private placement of units Closed: C$1.02M raised · C$0.6 a unit · 1 warrant at C$0.75 for 36 months · Centurion One Capital Corp. Dealers: Centurion One Capital Corp. (lead) Buyers: Dean Burns; Roger Jewett; Garth Webb; Doyle Stulting; J. Barton McRoberts; Michael Edwards Insiders: Directors Dean Burns (CEO), Roger Jewett (CFO), Garth Webb, Doyle Stulting, J. Barton McRoberts and Michael Edwards participated; related party transaction under MI 61-101 Use of proceeds: First-in-human clinical trials, ongoing research and development and general corporate purposes | Feb 10, 2026 | |
| Private placement of units Tranche closed: C$235,450 raised · C$0.6 a unit · Warrants at C$0.75 · Centurion One Capital Corp. Dealers: Centurion One Capital Corp. | Jan 2, 2026 | US$171,398 |
| Private placement of units Closed: C$1.12M raised · C$0.35 a unit · ½ warrant at C$0.5 for 24 months · Numus Capital Corp. Dealers: Numus Capital Corp. Buyers: Michael Edwards Insiders: Michael Edwards, a director of the Corporation, participated in the Private Placement. Use of proceeds: Ongoing research and development | Aug 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Research and development | 1.42M | 852.4K | 907.4K | 555.7K | 0 | |||
| Selling, general and administrative | 2.32M | 1.31M | 2.49M | 1.45M | 514.7K | 99.4K | ||
| Operating income | -4.00M | -2.43M | -3.61M | -2.18M | -598.2K | -172.5K | ||
| Depreciation and amortization | 149.4K | 134.3K | 117.6K | 102.2K | 83.5K | 73.1K | 66.8K | 60.6K |
| EBITDA | -3.85M | -2.29M | -3.49M | -2.08M | -514.7K | -99.4K | ||
| Interest expense | 1.35M | 639.1K | 29.3K | 26.6K | 0 | 0 | 0 | 0 |
| Income before tax | -5.37M | -3.06M | -3.64M | -2.22M | -598.2K | -172.5K | ||
| Net income | -5.37M | -3.02M | -3.64M | -2.22M | -598.2K | -172.5K | ||
| Earnings per share, basic | -0.04 | -0.03 | -0.03 | -0.02 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 464.0K | 195.2K | 235.8K | 602.1K | 83.9K | |||
| Short-term investments | 0 | 1.38M | 0 | |||||
| Receivables | 0 | 1.27K | 28.7K | 547 | 533 | 2.35K | ||
| Current assets | 1.25M | 1.65M | 311.0K | 673.0K | 112.6K | 1.39K | 2.19K | 3.00K |
| Total assets | 1.90M | 2.32M | 1.04M | 1.37M | 825.3K | |||
| Accounts payable | 472.4K | 229.4K | 546.9K | 167.4K | 55.2K | 33.7K | 3.90K | 7.63K |
| Current liabilities | 5.46M | 306.2K | 623.7K | 244.1K | 644.2K | 142.0K | 559.9K | 462.9K |
| Long-term debt | 389.4K | 3.95M | 321.6K | 292.3K | ||||
| Total liabilities | 5.85M | 4.26M | 945.3K | 536.5K | 1.10M | |||
| Shareholders' equity | -3.94M | -1.94M | 91.1K | 837.4K | -270.5K | |||
| Shares outstanding | 129.2M | 119.8M | 118.5M | 111.2M | 108.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.37M | -2.43M | -2.05M | -1.62M | -89.1K | -817 | 1.01K | -47.8K |
| Capital spending | -126.1K | -84.9K | -142.2K | -66.8K | -124.5K | 0 | 0 | 0 |
| Free cash flow | -3.49M | -2.51M | -2.19M | -1.69M | -213.6K | -817 | 1.01K | -47.8K |
| Cash from investing | -214.9K | -214.9K | -214.9K | -214.9K | ||||
| Cash from financing | 2.38M | 3.85M | 1.82M | 444.4K | 387.1K | 387.1K | 387.1K | 387.1K |
| Change in cash | 268.9K | -40.6K | -366.3K | -1.24M | 83.1K | -817 | 1.01K | -47.8K |
Cap table
Built by 6ix from Ocumetics Technology Corp’s releases · as of Aug 24, 2026
- Common shares
- 141,067,106
- Fully diluted
- 145,299,520
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 141,067,106 | Aug 24, 2026 |
| Warrants | 4,232,414 | Jul 31, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.50 · expire about Jul 2029 |
| Warrants · C$0.75 · expire about Dec 2028 |
| Warrants · C$0.50 · expire about Jul 2027 |
| Broker warrants · expiry not stated |
| Broker warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Aug 24, 2026 | 141,067,106 |
| Jul 31, 2026 | 140,662,106 |
| Jun 30, 2026 | 134,412,106 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Burwell | Director, Investor Relations · Since at least Oct 29, 2026 |
| Dean Burns | PRESIDENT / CEO / DIRECTOR · Since at least Oct 29, 2026 |
| Doyle Stulting | Chief Medical Officer · Since at least Jan 9, 2026 |
| Garth Webb | FOUNDER / CSO / DIRECTOR · Since at least Aug 31, 2026 |
| James Barton McRoberts | DIRECTOR · Since at least Nov 5, 2026 |
| Michael L. Edwards | DIRECTOR · Since at least Mar 11, 2025 |
| Raymond Marks | DIRECTOR · Since at least Feb 24, 2026 |
| Robert Quinn | DIRECTOR · Since at least Nov 5, 2026 |
| Roger Jewett | CFO / DIRECTOR · Since at least Sep 12, 2025 |
| Sandi Gilbert | Director · Since at least Oct 29, 2026 |
Log in to ask 6ix AI your own questions about Ocumetics Technology Corp.